A Phase 1b Trial of the IRX-2 Regimen and Nivolumab in Patients With Advanced Hepatocellular Cancer (HCC)
Phase of Trial: Phase I
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; IRX 2 (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 07 Mar 2019 Status changed from not yet recruiting to recruiting.
- 25 Jan 2019 Planned initiation date changed from 15 Dec 2018 to 15 Jun 2019.
- 07 Sep 2018 New trial record